- Home
- ACAD vs WSBC Comparison
ACAD vs WSBC Comparison
Compare ACAD & WSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- WSBC
- Stock Information
- Founded
- ACAD 1993
- WSBC 1870
- Country
- ACAD United States
- WSBC United States
- Employees
- ACAD N/A
- WSBC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- WSBC Major Banks
- Sector
- ACAD Health Care
- WSBC Finance
- Exchange
- ACAD Nasdaq
- WSBC Nasdaq
- Market Cap
- ACAD 2.5B
- WSBC 2.6B
- IPO Year
- ACAD 2004
- WSBC N/A
- Fundamental
- Price
- ACAD $21.57
- WSBC $30.78
- Analyst Decision
- ACAD Buy
- WSBC Buy
- Analyst Count
- ACAD 14
- WSBC 6
- Target Price
- ACAD $27.08
- WSBC $38.50
- AVG Volume (30 Days)
- ACAD 3.0M
- WSBC 443.2K
- Earning Date
- ACAD 05-07-2025
- WSBC 07-24-2025
- Dividend Yield
- ACAD N/A
- WSBC 4.81%
- EPS Growth
- ACAD N/A
- WSBC N/A
- EPS
- ACAD 1.37
- WSBC 1.44
- Revenue
- ACAD $996,283,000.00
- WSBC $569,805,000.00
- Revenue This Year
- ACAD $13.49
- WSBC $42.42
- Revenue Next Year
- ACAD $10.58
- WSBC $12.79
- P/E Ratio
- ACAD $15.76
- WSBC $21.33
- Revenue Growth
- ACAD 22.42
- WSBC N/A
- 52 Week Low
- ACAD $13.40
- WSBC $25.56
- 52 Week High
- ACAD $25.23
- WSBC $37.36
- Technical
- Relative Strength Index (RSI)
- ACAD 68.70
- WSBC 49.25
- Support Level
- ACAD $21.95
- WSBC $29.59
- Resistance Level
- ACAD $22.62
- WSBC $31.59
- Average True Range (ATR)
- ACAD 1.21
- WSBC 0.58
- MACD
- ACAD 0.23
- WSBC -0.13
- Stochastic Oscillator
- ACAD 56.27
- WSBC 41.90
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About WSBC WesBanco Inc.
Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.